K3769

KW-3902

Name: KW-3902
Brand: SIGMA
Price: 4170 CZK

≥98% (HPLC)

Synonym(s):

1,3-dipropyl-8-(3-noradamantyl)xanthine, 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione, MK-7418, Rolofylline

Slide 1 of 1

Select a Size

5 MG

CZK 4,170.00

Please contact Customer Service for Availability

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₈N₄O₂

CAS Number:

136199-02-5

Molecular Weight:

356.46

UNSPSC Code:

12352200

PubChem Substance ID:

329817141

NACRES:

NA.77

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

Key Documents

View All Documentation

Quality Level

100

assay

≥98% (HPLC)

form

solid

solubility

DMSO: 20 mg/mL, soluble

storage temp.

2-8°C

SMILES string

CCCN1C(=O)N(CCC)c2[nH]c(nc2C1=O)[C@]34C[C@H]5C[C@H](C[C@@H]3C5)C4

InChI

1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)/t12-,13+,14-,20-

InChI key

PJBFVWGQFLYWCB-OYEQCZOJSA-N

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	SML0422	F124	SML0366
Sigma-Aldrich K3769 KW-3902	Sigma-Aldrich SML0422 Istradefylline	Sigma-Aldrich F124 Furafylline	Sigma-Aldrich SML0366 Cipamfylline
assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
form solid	form powder	form powder	form powder
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. room temp	storage temp. 2-8°C
solubility DMSO: 20 mg/mL, soluble	solubility DMSO: 5 mg/mL (clear solution)	solubility DMSO: 10 mg/mL, clear	solubility DMSO: >10 mg/mL

Biochem/physiol Actions

KW-3902 is an A1 adenosine receptor antagonist and is over 800 fold more selective for an A1 receptor versus the A2A receptor.

KW-3902 is an A1 adenosine receptor antagonist.

Features and Benefits

This compound is featured on the Adenosine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

hcodes

H413

pcodes

P273 - P501

Hazard Classifications

Aquatic Chronic 4

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.

Beth Davison Weatherley et al.

Journal of cardiac failure, 16(1), 25-35 (2010-02-04)

Current treatment for acute decompensated heart failure (ADHF) is associated with incomplete resolution of symptoms and signs, recurrent symptoms of heart failure in-hospital and after discharge and high mortality. Studies have consistently demonstrated an association between worsening renal function in

Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study.

Christopher M O'Connor et al.

Circulation. Heart failure, 4(6), 724-732 (2011-09-09)

Cardiac troponin T (cTnT) elevation is common and is a predictor of outcomes in patients with acute heart failure (AHF). The degree and progression of cTnT release during hospitalization of patients with AHF is unclear. We evaluated the incidence of

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.

Gad Cotter et al.

Journal of cardiac failure, 14(8), 631-640 (2008-10-18)

Rolofylline, an adenosine A(1) receptor antagonist, facilitates diuresis and preserves renal function in patients with acute heart failure (AHF) with renal impairment. Although not powered around any specific hypothesis, this pilot study was designed to identify an efficacious dose while

The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.

John R Teerlink et al.

Drug safety, 35(3), 233-244 (2012-02-22)

Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes. The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A(1)-receptor antagonist, in patients with acute heart failure.

The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.

Michael M Givertz et al.

Journal of the American College of Cardiology, 50(16), 1551-1560 (2007-10-16)

This study sought to evaluate the dose-dependent effects of adenosine A1-receptor blockade on diuresis and renal function in patients with acute decompensated heart failure (ADHF) and renal impairment or diuretic resistance. Intravenous loop diuretics are the mainstay of therapy for

View All Related Papers

Articles

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Global Trade Item Number

SKU	GTIN
K3769-5MG	04061832082714
K3769-25MG	04061832082707

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

KW-3902